63 results
6-K
REPCF
Replicel Life Sciences Inc.
2 Jul 12
Current report (foreign)
12:00am
and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own … the potential to become the world’s first, minimally invasive solution for androgenetic alopecia and general hair loss in men and women
6-K
REPCF
Replicel Life Sciences Inc.
18 May 12
Current report (foreign)
12:00am
to advance our autologous DSCC therapy towards a successful treatment for pattern baldness in men and women,” concluded Mr. Hall.
About RepliCel Life … invasive solution for androgenetic alopecia and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology
6-K
REPCF
Replicel Life Sciences Inc.
12 Jul 11
Current report (foreign)
12:00am
in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair … first minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. These statements are only
6-K
REPCF
Replicel Life Sciences Inc.
15 Jun 12
Current report (foreign)
12:00am
for androgenetic alopecia and general hair loss in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s … and women.
These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans
6-K
REPCF
Replicel Life Sciences Inc.
13 Jun 11
Current report (foreign)
12:00am
in men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient’s hair cells from their own healthy hair … first minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. These statements are only
6-K
EX-99.1
9vghpl0x6mwf94cfk
12 Jul 13
Current report (foreign)
12:00am
6-K
EX-99.2
tpfsy5
12 Jul 13
Current report (foreign)
12:00am
6-K
ve244c1koc
13 Feb 13
Current report (foreign)
12:00am
6-K
EX-99.1
6cumaaqspqc5sce 6k
29 Oct 14
RepliCel Submits Clinical Trial Application to Health Canada for its Chronic Achilles Tendinosis Trial
12:00am
6-K
EX-99.1
vx5sxkclhjp9
1 Dec 14
RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis
12:00am
6-K
7fvo3yemnjd9k htrh
12 Sep 11
Current report (foreign)
12:00am
6-K
36msf0g
22 Mar 11
Current report (foreign)
12:00am
6-K
EX-99.2
8w03z11s33
28 Aug 13
Current report (foreign)
12:00am
6-K
EX-99.2
p3mlyuttadxygw6458
25 Nov 11
Condensed Consolidated Interim Financial Statements
12:00am
6-K
olxla23falzbb
26 Aug 11
Current report (foreign)
12:00am
6-K
EX-99.2
p3yx8 a71lo
29 May 14
Current report (foreign)
12:00am
6-K
16z71oz i9x8s
26 Nov 10
Current report (foreign)
12:00am